The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Living With HIV: Watch Aaron's Story
  • Email Email
  • Glossary Glossary
The Body Covers: The 39th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy
Poster Session 89-F: Novel Antiretroviral Agents

September 27, 1999

Amprenavir (APV) is the newest FDA-approved protease inhibitor, and like most drugs of this class it has shown good activity against HIV. It also has the advantage of requiring only twice-daily dosing. However, even less-frequent dosing, such as once a day, may help some people adhere to their medication schedule more easily, and lead to better outcomes. Also, the fewer the number of pills required per dose, the easier it is for most people. Amprenavir usually needs to be taken as 8 pills twice daily.

This abstract reports on the development of a compound related to APV, but with better solubility in water. In early studies it shows good blood levels and low toxicity. The greater water solubility may allow this compound to be given in substantially fewer pills per dose than APV. Further studies are ongoing to develop this drug for use against HIV.

Abstract: Discovery of VX-175/GW433908, a Novel, Water-Soluble Prodrug of Amprenavir (Paper 916)
Authored by: R. D. Tung, C. Baker, et al.

  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.